Ratings by JPMorgan (Chris Schott)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/18/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/7/2026 | Royalty Pharma | RPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/7/2026 | Elanco Animal Health | ELAN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/30/2026 | Teva Pharma | TEVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2026 | Biogen | BIIB | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/15/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/6/2026 | Merck | MRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/27/2026 | Perrigo Co. | PRGO | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/19/2026 | Elanco Animal Health | ELAN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/11/2026 | Viatris | VTRS | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/11/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/11/2026 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/2/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2026 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2026 | Merck | MRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Teva Pharma | TEVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/15/2025 | Perrigo Co. | PRGO | Maintain | Neutral (Neutral) |
|
Details | ||
| 11/18/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/11/2025 | Organon & Co. | OGN | Maintain | Underweight (Underweight) |
|
Details | ||
| 11/6/2025 | Teva Pharma | TEVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/6/2025 | Perrigo Co. | PRGO | Downgrade | Neutral (Overweight) |
20.19 (9.88) |
-51.06% | Details | |
| 11/5/2025 | Zoetis Inc. | ZTS | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | IDEXX Laboratories | IDXX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/31/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/16/2025 | Perrigo Co. | PRGO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/16/2025 | Organon & Co. | OGN | Maintain | Underweight (Underweight) |
|
Details | ||
| 10/7/2025 | Elanco Animal Health | ELAN | Upgrade | Overweight (Neutral) |
20.64 (24.25) |
17.49% | Details | |
| 10/3/2025 | Teva Pharma | TEVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/16/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/16/2025 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/16/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Elanco Animal Health | ELAN | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/7/2025 | Perrigo Co. | PRGO | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/1/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/30/2025 | Merck | MRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/11/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2025 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/7/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/9/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2025 | Teva Pharma | TEVA | Upgrade | Overweight (Neutral) |
18.07 (34.10) |
88.71% | Details | |
| 5/5/2025 | Biogen | BIIB | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/29/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2025 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2025 | Amneal Pharmaceuticals | AMRX | Upgrade | Overweight (Neutral) |
7.87 (17.61) |
123.76% | Details | |
| 2/12/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2025 | Merck | MRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/29/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2025 | Organon & Co. | OGN | Maintain | Underweight (N/A) |
|
Details | ||
| 1/27/2025 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 12/19/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2024 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 10/21/2024 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2024 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/11/2024 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/6/2024 | Amneal Pharmaceuticals | AMRX | Upgrade | Neutral (Underweight) |
8.49 (7.87) |
-7.3% | Details | |
| 9/6/2024 | Organon & Co. | OGN | Downgrade | Underweight (Neutral) |
22.22 (13.49) |
-39.29% | Details | |
| 8/2/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2024 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/26/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/26/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/24/2024 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/8/2024 | Teva Pharma | TEVA | Upgrade | Neutral (Underweight) |
13.71 (18.07) |
31.8% | Details | |
| 2/28/2024 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2024 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2024 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2024 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/25/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/25/2024 | Teva Pharma | TEVA | Maintain | Underweight (N/A) |
|
Details | ||
| 11/3/2023 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2023 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2023 | Amgen | AMGN | New Coverage | Neutral (N/A) |
280.60 (355.60) |
26.73% | Details | |
| 10/16/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/13/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/6/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2023 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2023 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2023 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/28/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/25/2023 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2023 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2023 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2023 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/7/2023 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2023 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2023 | Regeneron Pharma | REGN | Upgrade | Overweight (Neutral) |
724.55 (629.96) |
-13.05% | Details | |
| 12/16/2022 | Teva Pharma | TEVA | Maintain | Underweight (N/A) |
|
Details | ||
| 12/16/2022 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/14/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/14/2022 | EQRx, Inc. | EQRX | Downgrade | Underweight (Neutral) |
3.89 (2.34) |
-39.85% | Details | |
| 11/14/2022 | Teva Pharma | TEVA | Downgrade | Underweight (Neutral) |
9.40 (13.71) |
45.85% | Details | |
| 11/9/2022 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/17/2022 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/11/2022 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/4/2022 | Gilead Sciences | GILD | Upgrade | Overweight (Neutral) |
62.32 (125.45) |
101.3% | Details | |
| 9/30/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/8/2022 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/16/2022 | EQRx, Inc. | EQRX | New Coverage | Neutral (N/A) |
4.82 (2.34) |
-51.45% | Details | |
| 8/16/2022 | Elanco Animal Health | ELAN | Downgrade | Neutral (Overweight) |
20.08 (20.64) |
2.79% | Details | |
| 8/2/2022 | Regeneron Pharma | REGN | New Coverage | Neutral (N/A) |
581.69 (629.96) |
8.3% | Details | |
| 8/2/2022 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
59.75 (62.32) |
4.3% | Details | |
| 8/2/2022 | Biogen | BIIB | New Coverage | Neutral (N/A) |
215.06 (204.72) |
-4.81% | Details | |
| 8/2/2022 | Amgen | AMGN | New Coverage | Neutral (N/A) |
247.47 (280.60) |
13.39% | Details | |
| 7/28/2022 | Bausch Health Companies | BHC | Downgrade | Neutral (Overweight) |
8.68 (5.07) |
-41.59% | Details | |
| 7/18/2022 | Elanco Animal Health | ELAN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/13/2022 | Bausch Health Companies | BHC | New Coverage | Overweight (N/A) |
8.38 (8.68) |
3.58% | Details | |
| 4/14/2022 | Royalty Pharma | RPRX | Upgrade | Overweight (Neutral) |
41.81 (54.62) |
30.64% | Details | |
| 3/7/2022 | Coherus Biosciences | CHRS | Downgrade | Neutral (Overweight) |
11.56 (1.53) |
-86.76% | Details | |
| 3/1/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2021 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/12/2021 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2021 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/16/2021 | Elanco Animal Health | ELAN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2021 | Organon & Co. | OGN | New Coverage | Neutral (N/A) |
30.28 (22.22) |
-26.62% | Details | |
| 3/2/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2021 | Viatris | VTRS | Downgrade | Neutral (Overweight) |
14.85 (16.16) |
8.82% | Details | |
| 2/22/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2021 | Heska Corp. | HSKA | New Coverage | Overweight (N/A) |
172.71 (119.99) |
-30.53% | Details | |
| 1/29/2021 | IDEXX Laboratories | IDXX | New Coverage | Overweight (N/A) |
465.18 (559.88) |
20.36% | Details | |
| 11/16/2020 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/16/2020 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2020 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2020 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2020 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2020 | Horizon Therapeutics | HZNP | New Coverage | Overweight (N/A) |
71.53 (116.30) |
62.59% | Details | |
| 8/24/2020 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2020 | Repros Therapeutics | RPRX | New Coverage | Neutral (N/A) |
48.36 (54.62) |
12.94% | Details | |
| 6/1/2020 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2020 | Mallinckrodt plc | MNK | Downgrade | Underweight (Neutral) |
3.13 (0.34) |
-89.14% | Details | |
| 5/19/2020 | TherapeuticsMD | TXMD | Downgrade | Neutral (Overweight) |
1.17 (2.09) |
78.63% | Details | |
| 5/12/2020 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
87.90 (240.11) |
173.16% | Details | |
| 3/24/2020 | Perrigo Co. | PRGO | Upgrade | Overweight (Neutral) |
42.13 (20.19) |
-52.08% | Details | |
| 2/20/2020 | Pacira Pharmaceuticals | PCRX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/18/2019 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2019 | Bausch Health Companies | BHC | Upgrade | Overweight (Neutral) |
29.24 (5.07) |
-82.66% | Details | |
| 11/12/2019 | Teva Pharma | TEVA | Upgrade | Neutral (Underweight) |
9.30 (34.10) |
266.67% | Details | |
| 11/12/2019 | Amneal Pharmaceuticals | AMRX | Downgrade | Underweight (Neutral) |
1.61 (8.49) |
427.33% | Details | |
| 5/3/2019 | Bristol-Myers Squibb Co. | BMY | New Coverage | Overweight (N/A) |
46.88 (55.73) |
18.88% | Details | |
| 3/12/2019 | Eli Lilly | LLY | New Coverage | Overweight (N/A) |
126.70 (1119.65) |
783.7% | Details | |
| 12/11/2018 | Pfizer | PFE | Downgrade | Neutral (Overweight) |
44.40 (24.12) |
-45.68% | Details | |
| 10/15/2018 | Zoetis Inc. | ZTS | Upgrade | Overweight (Neutral) |
87.00 (79.17) |
-9% | Details | |
| 10/15/2018 | Elanco Animal Health | ELAN | New Coverage | Overweight (N/A) |
32.39 (24.25) |
-25.13% | Details | |
| 9/26/2018 | Eli Lilly | LLY | New Coverage | Overweight (N/A) |
105.59 (126.70) |
19.99% | Details |
